Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer
Sponsor: Roche Pharma AG
Terminated
others
Other terminated trials from Roche Pharma AG
- Breast Cancer · Phase PHASE2 · Jul 2022
- Recurrent B-Cell Non-Hodgkin Lymphoma · Phase PHASE1 · Apr 2021
- Breast Cancer · Phase PHASE2 · Nov 2016
- Chronic Lymphocytic Leukemia · Phase PHASE2 · Oct 2014
More terminations from Roche Pharma AG
Other Metastatic Colorectal Cancer trials with similar outcome
Listed as NCT02060669, this PHASE3 trial focuses on Metastatic Colorectal Cancer and remains terminated or withdrawn. Sponsored by Roche Pharma AG, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
-
Jan 2017 — May 2017 [monthly]
Unknown Status PHASE3
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roche Pharma AG
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .